Kymriah approval date?

See the DrugPatentWatch profile for Kymriah

What was the FDA approval date for Kymriah?

Kymriah, also known as tisagenlecleucel, is a chimeric antigen receptor (CAR)-T cell therapy used to treat certain types of cancer, including B-cell acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL) [1]. The FDA approved Kymriah on August 18, 2017.

What are the key implications of Kymriah's approval?

Kymriah's approval marked a significant milestone in the development of CAR-T cell therapies and paved the way for the treatment of other cancers [2]. As CAR-T cell therapies continue to emerge, companies like Novartis, the manufacturer of Kymriah, face challenges in maintaining market share and regulatory compliance [3].

Is Kymriah still a dominant player in the CAR-T cell market?

Although Kymriah was the first CAR-T cell therapy to be FDA-approved, other companies have since developed competing therapies, such as axicabtagene ciloleucel (Yescarta) [4]. As a result, the market for CAR-T cell therapies has become increasingly competitive [5].

Sources:

[1] FDA - Tisagenlecleucel (Kymriah) approval (2017)
[2] NEJM - Tisagenlecleucel for B-Cell Lymphomas (2017)
[3] Bloomberg - Novartis Challenges from Rivals for CAR-T Cell Therapy
[4] FDA - Axicabtagene ciloleucel (Yescarta) approval (2017)
[5] Forbes - Axicabtagene ciloleucel (Yescarta) Market Analysis (2022)
[6] DrugPatentWatch.com - Tisagenlecleucel (Kymriah) patent expiration information

Note: [6] provides up-to-date information on Kymriah's patent status and expiration date.